PharmEste – Product Pipeline Review – 2012 - Global Market Direct's pharmaceuticals report, "PharmEste - Product Pipeline Review - 2012" provides data on the PharmEste's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from our proprietary databases, PharmEste's corporate website, SEC filings, investor presentations and featured press releases, both from PharmEste and industry-specific third party sources, put together by our team.
Scope
- PharmEste - Brief PharmEste overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of PharmEste human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of PharmEste with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the PharmEste's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate PharmEste's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of PharmEste in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the PharmEste's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with PharmEste.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of PharmEste and identify potential opportunities in those areas.
Table of Contents
Table of Contents
List of Tables
List of Figures
PharmEste Snapshot
PharmEste Overview
Key Information
Key Facts
PharmEste – Research and Development Overview
Key Therapeutic Areas
PharmEste – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
PharmEste – Pipeline Products Glance
PharmEste Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
PharmEste – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
PharmEste – Drug Profiles
PHE-377
Product Description
Mechanism of Action
R&D Progress
PHE-575
Product Description
Mechanism of Action
R&D Progress
TRPA1 antagonists
Product Description
Mechanism of Action
R&D Progress
PharmEste – Pipeline Analysis
PharmEste – Pipeline Products by Therapeutic Class
PharmEste – Pipeline Products by Route of Administration
PharmEste – Pipeline Products By Mechanism of Action
PharmEste – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Financial Deals Landscape
PharmEste, Deals Summary
PharmEste, Pharmaceuticals & Healthcare, Deal Details
Venture Financing
PharmEste Secures Additional $2.56 Million In The Second Tranche Of Series B Round Of Financing
PharmEste Secures $8.67 Million In Series B Financing
PharmEste Secures $4.15 Million In Series A Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
PharmEste, Key Information
PharmEste, Key Facts
PharmEste – Pipeline by Indication, 2012
PharmEste – Pipeline by Stage of Development, 2012
PharmEste – Monotherapy Products in Pipeline, 2012
PharmEste – Phase I, 2012
PharmEste – Pre-Clinical, 2012
PharmEste – Discovery, 2012
PharmEste – Pipeline By Therapeutic Class, 2012
PharmEste – Pipeline By Route of Administration, 2012
PharmEste – Pipeline Products By Mechanism of Action, 2012
PharmEste, Other Locations
PharmEste, Deals Summary
PharmEste Secures Additional $2.56 Million In The Second Tranche Of Series B Round Of Financing
PharmEste Secures $8.67 Million In Series B Financing
PharmEste Secures $4.15 Million In Series A Financing
List of Figures
PharmEste – Pipeline by Indication, 2012
PharmEste – Pipeline by Stage of Development, 2012
PharmEste – Monotherapy Products in Pipeline, 2012
PharmEste – Pipeline By Therapeutic Class, 2012
PharmEste - Pipeline Products By Mechanism of Action, 2012 17